MA49688A - Procédés de traitement du syndrome myélodysplasique - Google Patents

Procédés de traitement du syndrome myélodysplasique

Info

Publication number
MA49688A
MA49688A MA049688A MA49688A MA49688A MA 49688 A MA49688 A MA 49688A MA 049688 A MA049688 A MA 049688A MA 49688 A MA49688 A MA 49688A MA 49688 A MA49688 A MA 49688A
Authority
MA
Morocco
Prior art keywords
treatment methods
syndrome treatment
myelodysplasic syndrome
myelodysplasic
methods
Prior art date
Application number
MA049688A
Other languages
English (en)
Inventor
Jacqueline Cirillo Bussolari
Aleksandra Rizo
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA49688(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geron Corp filed Critical Geron Corp
Publication of MA49688A publication Critical patent/MA49688A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA049688A 2017-07-28 2018-07-27 Procédés de traitement du syndrome myélodysplasique MA49688A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US201862685542P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
MA49688A true MA49688A (fr) 2020-06-03

Family

ID=63209674

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049688A MA49688A (fr) 2017-07-28 2018-07-27 Procédés de traitement du syndrome myélodysplasique

Country Status (17)

Country Link
US (1) US12171778B2 (fr)
EP (1) EP3658156B1 (fr)
JP (4) JP7316261B2 (fr)
KR (2) KR20250151565A (fr)
CN (2) CN110944646A (fr)
AU (2) AU2018307983B2 (fr)
BR (1) BR112020001749A2 (fr)
CA (1) CA3069010A1 (fr)
CL (2) CL2020000196A1 (fr)
IL (2) IL324714A (fr)
MA (1) MA49688A (fr)
MX (1) MX2025005894A (fr)
SG (1) SG11201913984RA (fr)
TW (2) TWI906757B (fr)
UA (1) UA127701C2 (fr)
WO (1) WO2019023667A1 (fr)
ZA (1) ZA202000070B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (fr) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
KR20250151565A (ko) 2017-07-28 2025-10-21 제론 코포레이션 골수형성이상 증후군의 치료 방법
AU2019389005B2 (en) * 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
KR20230041707A (ko) 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법
CN116887844A (zh) * 2021-01-18 2023-10-13 活跃生物技术有限公司 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
DK1210357T3 (da) 1999-09-10 2008-07-21 Geron Corp Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf
WO2001053307A1 (fr) 2000-01-21 2001-07-26 Geron Corporation 2'-arabino-fluorooligonucleotide n3'-→p5'phosphoramidates: leur synthese et utilisation
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
WO2002077184A2 (fr) 2001-03-23 2002-10-03 Geron Corporation Conjugues d'oligonucleotide
KR101298493B1 (ko) 2003-09-09 2013-08-21 제론 코포레이션 텔로머라제 억제를 위한 변형 올리고뉴클레오티드
US9133233B2 (en) 2003-11-04 2015-09-15 Geron Corporation RNA amidates and thioamidates for RNAi
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
ME02933B (fr) 2004-07-02 2018-04-20 Geron Corp Synthese de monomeres nucleosidiques a groupe 3'-amino protege
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (fr) 2005-04-15 2006-10-26 Geron Corporation Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
AR056682A1 (es) 2005-07-29 2007-10-17 Kalypsys Inc COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
EP4474480A2 (fr) 2006-10-30 2024-12-11 Geron Corporation Inhibiteur de télomérase combiné et gemcitabine pour le traitement du cancer
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
US8367078B2 (en) 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
NO3029154T3 (fr) 2008-10-17 2018-03-03
WO2011017096A2 (fr) 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Procédés de traitement de cancers hématologiques
WO2011098901A1 (fr) 2010-02-12 2011-08-18 Ipsogen Asxl1 en tant que nouveau marqueur diagnostique de néoplasies myéloïdes
CA2834218C (fr) 2011-04-29 2021-02-16 Sequenom, Inc. Quantification d'une minorite d'especes d'acide nucleique utilisant des oligonucleotides inhibiteurs
US20150005250A1 (en) 2011-10-13 2015-01-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Telomerase reverse transcriptase deficiency as diagnostic marker of myelodysplastic syndrome
KR20250086805A (ko) 2011-10-19 2025-06-13 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
WO2013095684A1 (fr) 2011-12-22 2013-06-27 Geron Corporation Analogues de guanine en tant que substrats de télomérase et affecteurs de la longueur de télomères
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
WO2014085632A1 (fr) 2012-11-30 2014-06-05 Geron Corporation Marqueurs de diagnostic pour le traitement de troubles de la prolifération cellulaire par des inhibiteurs de télomérase
US20150342982A1 (en) * 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
HRP20240624T1 (hr) * 2012-12-07 2024-08-02 Geron Corporation Inhibitor telomeraze imetelstat za liječenje mijeloproliferativnih poremećaja i mijeloproliferativne neoplazme
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2014160071A1 (fr) 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Procédés et compositions pour le traitement de cancers dépendants à la glutamine
PT3065828T (pt) * 2013-11-06 2019-04-01 Mayo Found Medical Education & Res Métodos e materiais para tratar malignidades hematológicas
EP3318276A1 (fr) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
KR20250151565A (ko) 2017-07-28 2025-10-21 제론 코포레이션 골수형성이상 증후군의 치료 방법

Also Published As

Publication number Publication date
KR20200033269A (ko) 2020-03-27
AU2018307983B2 (en) 2024-07-18
CN121243203A (zh) 2026-01-02
CN110944646A (zh) 2020-03-31
ZA202000070B (en) 2025-09-25
TWI906757B (zh) 2025-12-01
KR20250151565A (ko) 2025-10-21
JP2020528915A (ja) 2020-10-01
JP2025013669A (ja) 2025-01-24
US20190030064A1 (en) 2019-01-31
IL272163B1 (en) 2025-12-01
IL272163A (en) 2020-03-31
US12171778B2 (en) 2024-12-24
EP3658156B1 (fr) 2026-03-25
SG11201913984RA (en) 2020-02-27
AU2024219941A1 (en) 2024-10-10
JP2023009229A (ja) 2023-01-19
NZ760873A (en) 2024-03-22
AU2018307983A1 (en) 2020-02-13
JP7654761B2 (ja) 2025-04-01
UA127701C2 (uk) 2023-12-06
CL2020000196A1 (es) 2020-11-20
JP7316261B2 (ja) 2023-07-27
JP2024015000A (ja) 2024-02-01
IL324714A (en) 2026-01-01
CA3069010A1 (fr) 2019-01-31
TW201919705A (zh) 2019-06-01
MX2025005894A (es) 2025-06-02
BR112020001749A2 (pt) 2020-07-21
JP7654615B2 (ja) 2025-04-01
KR102867725B1 (ko) 2025-10-13
TWI879717B (zh) 2025-04-11
TW202432146A (zh) 2024-08-16
WO2019023667A1 (fr) 2019-01-31
CL2021001096A1 (es) 2021-11-12
EP3658156A1 (fr) 2020-06-03

Similar Documents

Publication Publication Date Title
EP3426250A4 (fr) Procédés de traitement
EP3601536A4 (fr) Procédés de traitement
EP3615010A4 (fr) Méthodes de traitement du syndrome de dravet
MA50056A (fr) Procédés de traitement de tumeur
EP3331550A4 (fr) Procédés de traitement de syndrome myéloprolifératif
EP3262407C0 (fr) Procédés et systèmes de traitement de cloisonnement
EP3388004A4 (fr) Instrument de traitement
EP3294065A4 (fr) Procédés de traitement du cancer
MA47095A (fr) Traitement du palais mou
MA47613A (fr) Compositions et procédés de traitement du cancer
EP3258883A4 (fr) Dispositifs, systèmes et procédés de traitement cardiaque
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3399861A4 (fr) Procédés de traitement du cancer par interféron
MA50569A (fr) Ensembles de remplissage-finition et procédés associés
EP3409744A4 (fr) Agent de traitement de surface
HUE066912T2 (hu) Lennox-Gastaut szindróma kezelési eljárása fenfluramin alkalmazásával
EP3341392A4 (fr) Compositions et procédés de traitement de la douleur
EP3846796A4 (fr) Méthodes de traitement du syndrome de libération de cytokine
MA49688A (fr) Procédés de traitement du syndrome myélodysplasique
MA47408A (fr) Traitement du cancer
EP3431566A4 (fr) Agent de traitement de surface
EP3375108A4 (fr) Traitement dewlan
EP3549358A4 (fr) Traitement audio
EP3525703A4 (fr) Dispositifs et procédés de traitement
EP3442946A4 (fr) Procédés de traitement du cancer